Blood Advances (May 2018)
Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants
- Anita J. Kumar,
- Soyoung Kim,
- Michael T. Hemmer,
- Mukta Arora,
- Stephen R. Spellman,
- Joseph A. Pidala,
- Daniel R. Couriel,
- Amin M. Alousi,
- Mahmoud D. Aljurf,
- Jean-Yves Cahn,
- Mitchell S. Cairo,
- Corey S. Cutler,
- Shatha Farhan,
- Usama Gergis,
- Gregory A. Hale,
- Shahrukh K. Hashmi,
- Yoshihiro Inamoto,
- Rammurti T. Kamble,
- Mohamed A. Kharfan-Dabaja,
- Margaret L. MacMillan,
- David I. Marks,
- Hideki Nakasone,
- Maxim Norkin,
- Muna Qayed,
- Olle Ringden,
- Harry C. Schouten,
- Kirk R. Schultz,
- Melhem M. Solh,
- Takanori Teshima,
- Alvaro Urbano-Ispizua,
- Leo F. Verdonck,
- Robert Peter Gale,
- Betty K. Hamilton,
- Navneet S. Majhail,
- Alison W. Loren
Affiliations
- Anita J. Kumar
- Tufts Medical Center, Boston, MA;; Anita J. Kumar, Tufts Medical Center, 800 Washington St, Box #245, Boston, MA 02111;
- Soyoung Kim
- Center for International Blood and Marrow Transplant Research, Department of Medicine, Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI;; Institute for Health and Society, Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI;
- Michael T. Hemmer
- Center for International Blood and Marrow Transplant Research, Department of Medicine, Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI;
- Mukta Arora
- Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN;
- Stephen R. Spellman
- Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN;
- Joseph A. Pidala
- Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;
- Daniel R. Couriel
- Utah Blood and Marrow Transplant Program, Salt Lake City, UT;
- Amin M. Alousi
- Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;
- Mahmoud D. Aljurf
- Department of Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia;
- Jean-Yves Cahn
- Department of Hematology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France;
- Mitchell S. Cairo
- Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, NY;
- Corey S. Cutler
- Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA;
- Shatha Farhan
- Henry Ford Hospital Bone Marrow Transplant Program, Wayne State University, Detroit, MI;
- Usama Gergis
- Hematolgic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, NY;
- Gregory A. Hale
- Department of Hematology/Oncology, Johns Hopkins All Children's Hospital, St. Petersburg, FL;
- Shahrukh K. Hashmi
- Department of Internal Medicine, Mayo Clinic, Rochester, MN;
- Yoshihiro Inamoto
- Fred Hutchinson Cancer Research Center, Seattle, WA;
- Rammurti T. Kamble
- Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX;
- Mohamed A. Kharfan-Dabaja
- Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;
- Margaret L. MacMillan
- University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN;
- David I. Marks
- Adult Bone Marrow Transplant, University Hospitals Bristol National Health Service Trust, Bristol, United Kingdom;
- Hideki Nakasone
- Jichi Medical University, Shimotsuke, Japan;
- Maxim Norkin
- Division of Hematology/Oncology, University Florida College of Medicine, Gainesville, FL;
- Muna Qayed
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA;
- Olle Ringden
- Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;
- Harry C. Schouten
- Department of Hematology, Academische Ziekenhuis, Maastricht, The Netherlands;
- Kirk R. Schultz
- Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, BC, Canada;
- Melhem M. Solh
- The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA;
- Takanori Teshima
- Kyushu University Hospital, Sapporo, Japan;
- Alvaro Urbano-Ispizua
- Department of Hematology, Hospital Clinic, University of Barcelona, Institut d'investigacions Biomediques August Pi i Sunyer, and Institute of Research Josep Carreras, Barcelona, Spain;
- Leo F. Verdonck
- Department of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands;
- Robert Peter Gale
- Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom;
- Betty K. Hamilton
- Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH;
- Navneet S. Majhail
- Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH;
- Alison W. Loren
- Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
- Journal volume & issue
-
Vol. 2,
no. 9
pp. 1022 – 1031
Abstract
Abstract: Optimal donor selection is critical for successful allogeneic hematopoietic cell transplantation (HCT). Donor sex and parity are well-established risk factors for graft-versus-host disease (GVHD), with male donors typically associated with lower rates of GVHD. Well-matched unrelated donors (URDs) have also been associated with increased risks of GVHD as compared with matched sibling donors. These observations raise the question of whether male URDs would lead to more (or less) favorable transplant outcomes as compared with parous female sibling donors. We used the Center for International Blood and Marrow Transplant Research registry to complete a retrospective cohort study in adults with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome, who underwent T-cell replete HCT from these 2 donor types (parous female sibling or male URD) between 2000 and 2012. Primary outcomes included grade 2 to 4 acute GVHD (aGVHD), chronic GVHD (cGVHD), and overall survival. Secondary outcomes included disease-free survival, transplant-related mortality, and relapse. In 2813 recipients, patients receiving male URD transplants (n = 1921) had 1.6 times higher risk of grade 2 to 4 aGVHD (P < .0001). For cGVHD, recipient sex was a significant factor, so donor/recipient pairs were evaluated. Female recipients of male URD grafts had a higher risk of cGVHD than those receiving parous female sibling grafts (relative risk [RR] = 1.43, P < .0001), whereas male recipients had similar rates of cGVHD regardless of donor type (RR = 1.09, P = .23). Donor type did not significantly affect any other end point. We conclude that when available, parous female siblings are preferred over male URDs.